Timing of future remyelination therapies and their potential to stop multiple sclerosis progression

Burcu Zeydan, Moses Rodriguez, Orhun H Kantarci

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Scopus citations

Abstract

Prior to the onset of demyelination in multiple sclerosis (MS), early oligodendrocyte injury, axonal degeneration and astroglial scarring occur. The irreversible progressive phase of MS begins when the axonal loss threshold is reached. Progressive disease onset has the highest impact on a poor prognosis in MS. Conversion to progressive disease is essentially an age-dependent process independent of disease duration and initial disease course. Although prevention of relapses has been the primary approach in the disease management, incomplete recovery from even the first relapse correlates with the long-term neurodegenerative phenotype of progressive MS onset. Therefore, the provider should review each patient’s potential for relapse-related disability and start DMDs with the goal of preventing relapses. Existing immunomodulatory medications used to prevent MS relapses do not prevent long-term disability, which requires agents focused on remyelination and axonal repair. If applied immediately after a relapse rather than during the progressive phase of MS, remyelination-stimulating strategies may result in full recovery and prevention of long-term neurodegeneration and progressive disease course.

Original languageEnglish (US)
Title of host publicationAdvances in Experimental Medicine and Biology
PublisherSpringer New York LLC
Pages161-170
Number of pages10
Volume958
DOIs
StatePublished - Jan 1 2017

Publication series

NameAdvances in Experimental Medicine and Biology
Volume958
ISSN (Print)00652598
ISSN (Electronic)22148019

Keywords

  • Axonal degeneration
  • Progressive MS
  • Remyelination

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Timing of future remyelination therapies and their potential to stop multiple sclerosis progression'. Together they form a unique fingerprint.

  • Cite this

    Zeydan, B., Rodriguez, M., & Kantarci, O. H. (2017). Timing of future remyelination therapies and their potential to stop multiple sclerosis progression. In Advances in Experimental Medicine and Biology (Vol. 958, pp. 161-170). (Advances in Experimental Medicine and Biology; Vol. 958). Springer New York LLC. https://doi.org/10.1007/978-3-319-47861-6_10